Literature DB >> 23581828

Successful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopenia.

Amir Ali Hamidieh1, Zahra Pourpak, Amir Hamdi, Mohammad Nabavi, Ardeshir Ghavamzadeh.   

Abstract

Idiopathic CD4+ lymphocytopenia (ICL) is a rare immunodeficiency disease with severe CD4 T-cell depletion, leading to serious opportunistic infections. The optimal treatment of ICL has not been determined, especially in severe form of the disease. Here, we report an eight-yr-old girl with ICL who was successfully treated with fludarabine-based conditioning HSCT. To the best of our knowledge, this is the first pediatric ICL case that was treated by HSCT. Allogeneic HSCT with a reduced intensity condition (RIC) regimen may be a feasible and curative treatment option in ICL patients with recurrent life-threatening complications.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581828     DOI: 10.1111/petr.12086

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

2.  Clinically HIV but negative serology: Think of idiopathic CD4(+) lymphocytopenia.

Authors:  Vidya Sanjay Nagar; Rahul Kadu; Shamshersingh Gajendra Chauhan; Rudrarpan Chatterjee; Aniruddha Kaushik; Deniskumar Vashrambhai Patel; Ankita Sood
Journal:  Indian J Crit Care Med       Date:  2016-06

Review 3.  Idiopathic CD4 Lymphocytopenia: Current Insights.

Authors:  Saravanakumari Vijayakumar; Stalin Viswanathan; Rajeswari Aghoram
Journal:  Immunotargets Ther       Date:  2020-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.